Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019

Major R&D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya programs expected to advance further in 2019

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, reported today its full year unaudited consolidated financial results for the year ending December 31, 2018. A brief unaudited report, including the profit and loss statement and the balance sheet, is available on the Company’s website,

A webcast for the financial community and media will be held today at 3:00 pm. (CET). A replay will be available on the Company’s website. Please refer to this link:

Read more

Financial statements are not audited. The audit procedures by the Statutory Auditors are underway. The Company plans to publish its audited annual financial report on or about March 21, 2018.